Skip to main content
AprilBio Co.,Ltd. logo

AprilBio Co.,Ltd. — Investor Relations & Filings

Ticker · 397030 ISIN · KR7397030008 KO Professional, scientific and technical activities
Open in API
Filings indexed 152 across all filing types
Latest filing 2023-03-06 AGM Information
Country KR South Korea
Listing KO 397030

About AprilBio Co.,Ltd.

http://www.aprilbio.com/en/

AprilBio is a biotechnology company that develops innovative biologic drugs, including therapeutic antibodies and recombinant proteins. The company's core is its proprietary SAFA (anti-Serum Albumin Fab-Associated) platform technology, which utilizes an albumin-binding antibody fragment to create long-acting therapeutics. This platform is designed to enhance the efficacy, safety, and plasma half-life of drug candidates while minimizing adverse effects. AprilBio's research and development pipeline focuses on addressing unmet medical needs in therapeutic areas such as autoimmune diseases, oncology, and other inflammatory and rare diseases. The company advances new drug candidates through early clinical development stages for potential technology transfer.

Recent filings

Filing Released Lang Actions
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a shareholder meeting (주주총회소집결의) issued by AprilBio. It outlines the date, location, and agenda items for the upcoming Annual General Meeting (AGM). Since this document serves as the official notification and solicitation of shareholder attendance for the meeting, it falls under the Proxy Solicitation & Information Statement category.
2023-03-06 Korean
주주총회집중일개최사유신고
AGM Information Classification · 98% confidence The document is a formal regulatory filing submitted to the KRX (Korea Exchange) regarding the 'Reason for holding a General Meeting of Shareholders on a concentrated date'. It explains why the company scheduled its AGM on a date that coincides with other companies' meetings. Since this is a specific regulatory disclosure required by the exchange regarding meeting logistics rather than the meeting materials themselves, the AGM results, or a proxy statement, it falls under the general regulatory filing category.
2023-03-06 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from a Korean company (AprilBio) announcing a significant change (over 30%) in revenue or profit structure. This is a standard regulatory disclosure requirement in the Korean market (DART system) for listed companies to report material financial fluctuations before the final audit is completed. Since it is a specific regulatory disclosure of financial performance data rather than a full report or a simple announcement of a report's availability, it falls under the 'Regulatory Filings' category. FY 2022
2023-02-09 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory notice regarding the setting of a record date and shareholder register closure for an upcoming Annual General Meeting (AGM). It does not contain the full AGM materials or proxy statements, but rather serves as a formal regulatory notification of the administrative process for the meeting. Given the nature of the announcement regarding shareholder rights and meeting preparation, it falls under the general regulatory filing category.
2022-12-14 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a short announcement regarding an upcoming Investor Relations (IR) event (Corporate Day). It provides details such as the date, location, purpose, and contact information for the event. Since it is an announcement of an event rather than the presentation slides themselves, and it is under 5,000 characters, it falls under the category of a regulatory filing announcement regarding corporate activities.
2022-11-25 Korean
분기보고서 (2022.09)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for the company 'AprilBio Co., Ltd.' (주식회사 에이프릴바이오) covering the period from January 1, 2022, to September 30, 2022. It contains detailed corporate information, business descriptions, financial data, and management disclosures, which are characteristic of an interim financial report. It is not a mere announcement or certification, but the full report itself. 9M 2022
2022-11-10 Korean

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.